Summarized by Masters of Longevity from Longevity Technology.
AI-designed senolytic immunotherapy research: a news article previewing preclinical progress and plans to move an off-the-shelf peptide candidate toward clinical development.
Key Takeaways
- Immorta Bio completed planned preclinical studies for an AI-designed nine–amino-acid peptide immunotherapy named SenoMune-0257.
- Preclinical data showed SenoMune-0257 stimulated cytotoxic T cells that selectively eliminated senescent cells while sparing healthy cells under test conditions.
- Immorta Bio plans to advance SenoMune-0257 into clinical development in 2026 and positions it as an off-the-shelf alternative to personalized cellular therapies.
